Páll Karlsson

Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Alexander Hincker, Washington University Pain Center, Washington University School of Medicine, St Louis, MO, United States.
  • ,
  • Karen Frey, Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, United States.
  • ,
  • Lesley Rao, Washington University Pain Center, Washington University School of Medicine, St Louis, MO, United States.
  • ,
  • Nina Wagner-Johnston, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • ,
  • Arbi Ben Abdallah, Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, United States.
  • ,
  • Benjamin Tan, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, United States.
  • ,
  • Manik Amin, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, United States.
  • ,
  • Tanya Wildes, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, United States.
  • ,
  • Rajiv Shah, Washington University Pain Center, Washington University School of Medicine, St Louis, MO, United States.
  • ,
  • Pall Karlsson
  • Kristopher Bakos, Investigation Drug Service, Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, United States.
  • ,
  • Katarzyna Kosicka, Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznan, Poland.
  • ,
  • Leonid Kagan, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, United States.
  • ,
  • Simon Haroutounian, Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, United States., Washington University Pain Center, Washington University School of Medicine, St Louis, MO, United States.

Painful chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and treatment-resistant sequela of many chemotherapeutic medications. Ligands of α2δ subunits of voltage-gated Ca channels, such as pregabalin, have shown efficacy in reducing mechanical sensitivity in animal models of neuropathic pain. In addition, some data suggest that pregabalin may be more efficacious in relieving neuropathic pain in subjects with increased sensitivity to pinprick. We hypothesized that greater mechanical sensitivity, as quantified by decreased mechanical pain threshold at the feet, would be predictive of a greater reduction in average daily pain in response to pregabalin vs placebo. In a prospective, randomized, double-blinded study, 26 patients with painful CIPN from oxaliplatin, docetaxel, or paclitaxel received 28-day treatment with pregabalin (titrated to maximum dose 600 mg per day) and placebo in crossover design. Twenty-three participants were eligible for efficacy analysis. Mechanical pain threshold was not significantly correlated with reduction in average pain (P = 0.97) or worst pain (P = 0.60) in response to pregabalin. There was no significant difference between pregabalin and placebo in reducing average daily pain (22.5% vs 10.7%, P = 0.23) or worst pain (29.2% vs 16.0%, P = 0.13) from baseline. Post hoc analysis of patients with CIPN caused by oxaliplatin (n = 18) demonstrated a larger reduction in worst pain with pregabalin than with placebo (35.4% vs 14.6%, P = 0.04). In summary, baseline mechanical pain threshold tested on dorsal feet did not meaningfully predict the analgesic response to pregabalin in painful CIPN.

OriginalsprogEngelsk
TidsskriftPain
Vol/bind160
Nummer8
Sider (fra-til)1835-1846
Antal sider12
ISSN0304-3959
DOI
StatusUdgivet - aug. 2019
Eksternt udgivetJa

Se relationer på Aarhus Universitet Citationsformater

ID: 159941480